A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

NCT03793725 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: SHR1210
DRUG: Apatinib

Sponsor

Yanqiao Zhang

Collaborators

[object Object]